Literature DB >> 27800622

Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy.

Pei-Chi Yang1, Jonathan D Moreno2, Mao-Tsuen Jeng1, Xander H T Wehrens3, Sergei Noskov4, Colleen E Clancy5.   

Abstract

Year:  2016        PMID： 27800622      PMCID： PMC5088243          DOI： 10.1113/JP273143

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  24 in total

1.  Local anesthetic and antiepileptic drug access and binding to a bacterial voltage-gated sodium channel.

Authors:  Céline Boiteux; Igor Vorobyov; Robert J French; Christopher French; Vladimir Yarov-Yarovoy; Toby W Allen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

2.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

3.  Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

Authors:  Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

Review 4.  PIP2 is a necessary cofactor for ion channel function: how and why?

Authors:  Byung-Chang Suh; Bertil Hille
Journal:  Annu Rev Biophys       Date:  2008       Impact factor: 12.981

5.  Effects of eicosapentaenoic acid on cardiac SR Ca(2+)-release and ryanodine receptor function.

Authors:  J S Swan; K Dibb; N Negretti; S C O'Neill; R Sitsapesan
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

6.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Authors:  Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann
Journal:  Nat Med       Date:  2009-03-29       Impact factor: 53.440

7.  The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.

Authors:  Godfrey L Smith; Niall MacQuaide
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

8.  In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Pei-Chi Yang; Jonathan D Moreno; Christina Y Miyake; Steven B Vaughn-Behrens; Mao-Tsuen Jeng; Eleonora Grandi; Xander H T Wehrens; Sergei Y Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2015-12-30       Impact factor: 5.182

9.  Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Alan J Williams; Mark L Bannister; N Lowri Thomas; Markus B Sikkel; Saptarshi Mukherjee; Chloe Maxwell; Kenneth T MacLeod; Christopher H George
Journal:  J Physiol       Date:  2016-11-01       Impact factor: 5.182

10.  Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.

Authors:  Markus B Sikkel; Thomas P Collins; Christina Rowlands; Mit Shah; Peter O'Gara; Alan J Williams; Sian E Harding; Alexander R Lyon; Kenneth T MacLeod
Journal:  Cardiovasc Res       Date:  2013-01-19       Impact factor: 10.787
View more
  1 in total

Review 1.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.